Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

71%

5 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4

3(42.9%)

Phase 3

2(28.6%)

Phase 1

2(28.6%)

7Total

Phase 4(3)

Phase 3(2)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06285370Phase 4Active Not Recruiting

A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy

Role: lead

NCT02868060Phase 1Completed

Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP)

Role: lead

NCT02868099Phase 3Completed

Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP)

Role: lead

NCT03123406Phase 4Completed

Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT

Role: lead

NCT03822507Phase 3Completed

Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia

Role: collaborator

NCT04614298Phase 4Withdrawn

A Phase 4 Study of Brodalumab (KHK4827) in Subjects With Moderate to Severe Plaque Psoriasis

Role: collaborator

NCT04206657Phase 1Completed

Pharmacokinetic Study of KHK7580 in Healthy Adult Volunteers

Role: collaborator

All 7 trials loaded